Victoria Djukic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Djukic has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jens Klotz
Department of Radiation Oncology, RWTH Aachen University, Pauwelsstrasse 30, 52072 Aachen, Germany
2 shared publications - Marc D. Piroth
Department of Radiation Oncology, RWTH Aachen University Hospital, Aachen, Germany
2 shared publications - Michael J. Eble
Department of Radiation Oncology, RWTH Aachen University, 52074 Aachen, Germany
2 shared publications - Michael Pinkawa
Department of Radiation Oncology, Wege Klinik, Bonn, Germany
2 shared publications - Richard Holy
Department of Radiation Oncology, RWTH Aachen University, Pauwelsstrasse 30, 52072 Aachen, Germany
2 shared publications - Axel Heidenreich
RWTH University Aachen
1 shared publication
Latest Publications
- Open Access
- 10 December 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 209
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT; 70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up period after RT was 68 months. Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS, DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS of 27% after EBRT and 20% after EBRT with HDR-BT). Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason score>6 and patient age were found to be predictive for lower OS (p0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence. An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings.
- 10 December 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 209
Open AccessLocal prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT; 70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up period after RT was 68 months. Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS, DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS of 27% after EBRT and 20% after EBRT with HDR-BT). Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason score>6 and patient age were found to be predictive for lower OS (p0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence. An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings.
- Open Access
- 30 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 14
Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost
In comparison to the conventional whole-prostate dose escalation, an integrated boost to the macroscopic malignant lesion might potentially improve tumor control rates without increasing toxicity. Quality of life after radiotherapy (RT) with vs. without 18F-choline PET-CT detected simultaneous integrated boost (SIB) was prospectively evaluated in this study.
- 30 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 14
Open AccessDose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost
In comparison to the conventional whole-prostate dose escalation, an integrated boost to the macroscopic malignant lesion might potentially improve tumor control rates without increasing toxicity. Quality of life after radiotherapy (RT) with vs. without 18F-choline PET-CT detected simultaneous integrated boost (SIB) was prospectively evaluated in this study.